Navigation Links
Cell Therapeutics, Inc. Adopts Shareholder Rights Plan
Date:12/28/2009

SEATTLE, Dec. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on December 24, 2009, CTI's Board of Directors (the "Board of Directors") approved and adopted a Shareholder Rights Plan (the "Rights Plan") in which one preferred stock purchase right will be distributed for each common share held as of the close of business on January 7, 2010. Initially, the rights are not exercisable, and are attached to and trade with, all of the shares of CTI's common stock outstanding as of, and issued subsequent to, the record date.

"This is a critical turning point as CTI prepares for the potential launch of pixantrone, a product which we believe has significant commercial prospects for CTI and its shareholders," said James A. Bianco, M.D., CEO of CTI. "The Board of Directors believes that the Rights Plan will enhance CTI's ability to protect shareholder interests and enable shareholders to receive fair treatment in the event of an unsolicited takeover attempt. The Rights Plan is intended to provide the Board of Directors with sufficient time to consider any and all alternatives to enhance value for our shareholders."

The Rights Plan is designed to deter coercive takeover tactics, and to prevent an acquirer from gaining control of CTI without offering a fair price to all of CTI's shareholders. The Rights Plan will not prevent a takeover, but should encourage anyone seeking to acquire CTI to negotiate with the Board of Directors prior to attempting a takeover.

Each right, if and when it becomes exercisable, will entitle the holder to purchase one tenthousandth of a share of a new series of junior participating cumulative preferred stock for $6.00, subject to standard adjustment in the Rights Plan. The rights will become exercisable for CTI preferred stock if a person or group acquires 20% or more of CTI's common stock. Upon acquisition of 20% or more of
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)...  AbbVie (NYSE: ABBV ) will participate ... March 12, 2015. Richard A. Gonzalez , chairman ... and answer session at 8:30 a.m. Central time. ... be accessible through AbbVie,s Investor Relations Web site at ... will be available later that day. ...
(Date:3/6/2015)... Alemania, 6 de marzo de 2015 ... de gestión empresarial de imagen médica, fortalece su ... nombramiento de Randolph Sternberg como director ... como director de operaciones. Logo - ... será responsable de las ventas y desarrollo ...
(Date:3/5/2015)... 5, 2015   MeridianRx earned highest ... seven optional leading indicators during its recent URAC ... "We are very proud of earning this level ... , Chief Operating Officer of MeridianRx. "It is ... to transparency, flexibility and innovation." URAC,s ...
Breaking Medicine Technology:TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3MeridianRx Earns Highest URAC Accreditation Status 2
... May 4 With today,s announcement of a new ... leadership in health information technology (HIT) has now attracted $49.5 ... Reinvestment Act (ARRA). , , ... The latest grant comes through the Beacon Communities Cooperative Agreement ...
... NEW ORLEANS , May 4 ... with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 ...   Traficet-EN maintained a clinical remission rate (Crohn,s Disease ... in Crohn,s patients over the course of 36 weeks, ...
Cached Medicine Technology:Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 2Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 3Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 2ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 3ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 5ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 6
(Date:3/6/2015)... 2015 At Natural Products Expo ... the launch of its powerful, location-aware iOS app ... sustainable products at any retailer that carries those ... Expo West Booth 6054. , Makeena’s proprietary ... non-GMO, organic, Paleo, and vegan, among many other ...
(Date:3/6/2015)... La (PRWEB) March 06, 2015 Many ... function despite medical therapy. If you (or someone you ... to knee osteoarthritis, you may be interested in the ... Covington Orthopedic announced today that he is one of ... Cytori Therapeutics to begin enrolling subjects as part of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 In a new ... Polish mesothelioma patients reported that shoulder pain was their first ... on its website. Click here to read it now. ... analyzed the medical records of 49 mesothelioma patients ... reported that it was shoulder pain that first prompted them ...
(Date:3/6/2015)... 06, 2015 Los Angeles cosmetic dentist ... for Zoom whitening. Zoom is a special type of teeth ... Unlike other teeth whitening treatments, Zoom does its job in ... stains. For a limited time, Dr. Ghasri is offering Zoom ... usual price of $650 and allows patients to try out ...
(Date:3/6/2015)... As the Mayo Clinic's 2012 published Benicar ... Associates Nationwide Legal Services, A.P.C., comments on these findings ... v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in US ... light of a recently filed lawsuit, Ford & Associates ... explore the Mayo Clinic's Benicar case study findings purportedly ...
Breaking Medicine News(10 mins):Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, is Now Offering a Promotion on Zoom Whitening 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4
... Mylan Pharmaceuticals Inc. has received final approval from the ... Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules ... generic version of Eli Lilly and Company's Prozac(R) Capsules. ... for the 12 months ending March 31, 2007, for ...
... set high staffing standards for elder care in nursing homes ... staff nurses to prevent serious safety violations, according to ... of Nursing. ,The majority of the nation's elderly ... is well below national recommendations for safe care, the study ...
... ocean measurements and by analysing climate simulations we can see ... be explained by natural variability',said CSIRO oceanographer Dr Gael Alory. ... to changes in the heat structure of the atmosphere and ... sub-tropical Indian Ocean of around two degrees celsius. ...
... brand ambassadors of India. But they could also prove a ... case of Thirumurthy Nakka Boomaiah , 35 and hailing ... ,He has been sentenced to 69 days in ... London to Philadelphia and assaulting flight attendants. But he has ...
... during pregnancy could be harmful, according to an Iranian university ... anemia in pregnancy but many women take extra iron. Anemia ... enough oxygen due to low number of red blood cells ... normal amounts of oxygen. Common symptoms of anemia include feeling ...
... who were treated at Presbyterian Hospital of Dallas for ... the hospital and doctors there took part in a ... women's problems. ,According to the complaint filed ... a patient in Presbyterian's Eating Disorder Program. There, psychiatrist ...
Cached Medicine News:Health News:Policy Changes Have Direct Effect on Nursing Home Care 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 3Health News:Climate Change Signal Detected in the Indian Ocean 2Health News:Indian Engineer Sentenced for Groping Women During Flight 2Health News:Anorexia Patients Sue Dallas' Presbyterian Hospital 2
... Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No ... 0.2-2 Inaccuracy (%) ... Imprecision(%) ... 0.01 Dimensions: ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
Developed specifically for the 5000/5500 ultrasound consoles....
Medicine Products: